Mycoplasma gallisepticum and Mycoplasma synoviae antigens (MG/MS antigens)

Mycoplasma gallisepticum (MG) and Mycoplasma synoviae (MS) are the primary mycoplasmal pathogens affecting poultry, causing chronic respiratory disease, infectious synovitis, and significant economic losses in the global poultry industry. The antigens of these organisms, particularly surface lipoproteins and adhesins such as GapA, CrmA, and the variable lipoprotein hemagglutinin (VlhA) family, are essential for the bacteria's ability to adhere to host respiratory epithelium and evade immune detection through high-frequency antigenic variation (Source: PubMed, PMID: 25233355). These antigens are the primary targets for veterinary vaccines, including live attenuated and inactivated (bacterin) formulations, which aim to reduce clinical disease severity and vertical transmission to offspring (Source: Merck Veterinary Manual). While antibiotics like macrolides, tetracyclines, and fluoroquinolones are used to treat infections by targeting bacterial protein synthesis or DNA replication, the antigens themselves are the focus of immunoprophylaxis and diagnostic serology. This entry is considered 'incorrect' as a single target because it combines multiple distinct proteins from two different bacterial species into a single category, whereas therapeutic development typically targets specific molecular entities.

Other names

Avian mycoplasma antigensMG/MS surface proteinsMycoplasma gallisepticum/synoviae lipoproteinsPoultry mycoplasma antigens

Induction of active immunity through the presentation of bacterial antigens to the host immune system, leading to the production of specific antibodies (humoral immunity) and activation of T-cells (cellular immunity) to prevent bacterial attachment and colonization of the respiratory tract.